AUM $38.6MER 0.65%NAV $40.68Holdings 198Inception Dec 2014
Price Chart
Key Statistics
Previous Close
$42.22Day Range
$42.29$43.38
52-Week Range
$19.19$47.75
Avg Volume
13.5KDividend Yield
1.54%Expense Ratio
0.65%AUM
$38.6MShares Outstanding
850.1KETF Grades
?ETF Grades compare this fund against others in the same category using percentile rankings across six factors. Grades range from A+ (top 5%) to F (bottom 20%). Updated daily.Sector Breakdown
| Sector | Weight % |
|---|---|
| Healthcare | 100.00% |
Country Allocation
| Country | Weight % |
|---|---|
| United States | 87.46% |
| United Kingdom | 3.23% |
| Netherlands | 2.82% |
| Canada | 2.36% |
| Ireland | 2.01% |
| Switzerland | 0.98% |
| Germany | 0.79% |
| Singapore | 0.28% |
| Other | 0.07% |
Fund Information
- Issuer
- Virtus
- Category
- Healthcare
- Types
- Biotech
- Inception Date
- Dec 16, 2014
- Exchange
- NYSE_ARCA
- Description
- The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index, which tracks the performance of select clinical trials stage biotechnology companies.Effective February 27, this Fund's name changed from Virtus LifeSci Biotech Clinical Trials ETF to Virtus Biotech Clinical Trials ETF.
Similar ETFs
The Virtus Biotech Clinical Trials ETF (BBC) is an exchange-traded fund issued by Virtus that launched on Dec 16, 2014. It currently manages $38.6M in assets under management. The fund charges an expense ratio of 0.65%. The fund holds 198 securities in its portfolio. It falls under the Healthcare category.
Top 10 holdings represent 18.8% of the fund
| Rank | Symbol | Name | Weight % | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | ERAS | Erasca Inc | 3.05% | 87,082 | $1.2M |
| 2 | TNGX | Tango Therapeutics Inc | 2.50% | 33,529 | $1000K |
| 3 | SYRE | Spyre Therapeutics Inc | 1.88% | 9,324 | $753K |
| 4 | ELVN | Enliven Therapeutics Inc | 1.87% | 18,593 | $750K |
| 5 | ORKA | Oruka Therapeutics Inc | 1.78% | 10,387 | $711K |
| 6 | LQDA | Liquidia Corp | 1.68% | 9,392 | $673K |
| 7 | RZLT | Rezolute Inc | 1.68% | 174,163 | $672K |
| 8 | DFTX | Definium Therapeutics Inc | 1.50% | 24,979 | $602K |
| 9 | RVMD | Revolution Medicines Inc | 1.48% | 3,972 | $593K |
| 10 | ALMS | Alumis Inc | 1.42% | 27,284 | $570K |
| 11 | DNTH | Dianthus Therapeutics Inc | 1.42% | 7,440 | $569K |
| 12 | RLAY | Relay Therapeutics Inc | 1.39% | 39,040 | $556K |
| 13 | CMPS | Compass Pathways Plc | 1.32% | 46,512 | $531K |
| 14 | GHRS | GH Research PLC | 1.24% | 24,050 | $497K |
| 15 | CNTA | Centessa Pharmaceuticals PLC | 1.17% | 11,825 | $470K |
Page 1 of 4
Detailed Returns
| Period | Return | ETF |
|---|---|---|
| 1D | +2.13% | |
| 1W | +5.21% | |
| 1M | +1.39% | |
| 3M | +3.71% | |
| 6M | +11.54% | |
| YTD | +17.06% | |
| 1Y | +116.70% | |
| 3Y | +67.59% | |
| 5Y | -14.95% |
Moving Averages
20-Day MA
$42.37
Above 20-Day MA50-Day MA
$43.89
Below 50-Day MA200-Day MA
$37.19
Above 200-Day MAPrice with Moving Averages
Support & Resistance
52-Week High
$47.75
Current Price
$43.12
52-Week Low
$19.19
$19.19$47.75
Current Yield
1.54%
Annual Dividend
$1.2745
Frequency
1x/year
Last Ex-Date
Dec 22, 2025
Dividend History
| Ex-Date | Amount | Pay Date |
|---|---|---|
| Dec 22, 2025 | $0.6554 | Dec 29, 2025 |
| Dec 20, 2024 | $0.2395 | Dec 27, 2024 |
| Dec 20, 2023 | $0.0823 | Dec 29, 2023 |
| Dec 20, 2017 | $0.2972 | Dec 27, 2017 |
| Dec 21, 2015 | $0.1473 | Dec 29, 2015 |
Dividend Payments Over Time
Category Comparison
| Metric | BBC | Healthcare(176 ETFs) | Biotech(41 ETFs) |
|---|---|---|---|
| Fund Info | |||
| Expense Ratio | 0.65% | 0.61% | 0.83% |
| AUM | $38.6M | $910.0M | $1.52B |
| Dividend Yield | 1.54% | 3.35% | 1.97% |
| Avg Volume | 13.5K | 275.1K | 871.8K |
| Holdings | 198 | 99 | 65 |
| Performance | |||
| 1-Month Return | -4.29% | +1.77% | +4.73% |
| 6-Month Return | +8.09% | +3.26% | +5.11% |
| YTD Return | +11.59% | +3.61% | +6.25% |
| 1-Year Return | +112.81% | +24.59% | +37.13% |
Compare with Another ETF
Search for an ETF to compare with BBC:
FREE DOWNLOAD
The Beginner's Guide to ETFs
20 pages. Zero fluff. Everything you need to start investing in ETFs.
No spam. Unsubscribe anytime.